33860-28-5

Basic information

• Product Name: 4-METHYLPIPERAZINE-1-CARBOTHIOAMIDE
• Synonyms: 4-methylpiperazine-1-carbothioamide(SALTDATA: FREE);4-Methyl-1-piperazinyl-thiocarboxaMide;4-methyl-1-Piperazinecarbothioamide
• CAS NO: 33860-28-5
• Molecular Formula: C₆H₁₃N₃S
• Molecular Weight: 159.25
• Mol File: 33860-28-5.mol

Chemical Properties

• Boiling Point: 247.2°Cat760mmHg
• Flash Point: 103.3°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 0.026mmHg at 25°C
• PKA: 16.22±0.20(Predicted)
• CAS DataBase Reference: 4-METHYLPIPERAZINE-1-CARBOTHIOAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHYLPIPERAZINE-1-CARBOTHIOAMIDE(33860-28-5)
• EPA Substance Registry System: 4-METHYLPIPERAZINE-1-CARBOTHIOAMIDE(33860-28-5)

Safety Data

• Hazardous Substances Data: 33860-28-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H13N3S/c1-8-2-4-9(5-3-8)6(7)10/h2-5H2,1H3,(H2,7,10)/p+1

Upstream product

• 50398-09-9 N-methylpiperazine dihydrochloride 
• 109-01-3 1-methyl-piperazine 
• 6160-65-2 1,1'-Thiocarbonyldiimidazole 
• 18739-36-1 4-methyl-piperazine-1-carbothioyl chloride 
• 333-20-0 potassium thioacyanate 
• 88681-68-9 di(1H-imidazol-2-yl)methanethione 
• 1039455-83-8 imidazol-1-yl-(4-methyl-piperazin-1-yl)-methanethione 

Downstream Products

• 294622-47-2 4-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzoic acid 
• 909707-15-9 C₁₄H₁₆BrN₃S 
• 1094358-13-0 Methyl 3-fluoro-4-[2-(4-methylpiperazin-1-yl)-thiazol-4-yl]benzoate 
• 1160623-75-5 N-(3-(5-(2-chloro-4-pyrimidinyl)-2-(4-methyl-1-piperazinyl)-1,3-thiazol-4-yl)phenyl)-2,6-difluorobenzamide 
• 1307271-61-9 N-{2-fluoro-3-[5-(2-{[(2S)-2-hydroxypropyl]amino}-4-pyrimidinyl)-2-(4-methyl-1-piperazinyl)-1,3-thiazol-4-yl]phenyl}-1-propanesulfonamide 
• 1307272-05-4 N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(4-methyl-1-piperazinyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-1-propanesulfonamide 
• 1394938-83-0 N-{2,4-difluoro-3-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-phenyl}-2,5-difluoro-benzenesulfonamide 
• 1059549-57-3 4-[5-fluoro-2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzoic acid methyl ester 
• 860344-60-1 3-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzoic acid 
• 219598-17-1 2(S)-<(2-benzoylphenyl)amino>-3-<4-<2-<5-methyl-2-(4-methylpiperazin-1-yl)thiazol-4-yl>ethoxy>phenyl>propionic acid methyl ester 
• 294623-49-7 CRA-03783 

Relevant articles and documents

THIAZOLE AND OXAZOLE KINASE INHIBITORS

The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

Furanone derivatives as cysteine protease inhibitors

Compounds of the Formula II wherein R1 is H, OH, F R2 is -CH2CH(CH3)2, -CHC(CH2)3 or CH(CH3)(CH2CH3); R2' is H; or R2 and R

Design and synthesis of tetracyclic nonpeptidic biaryl nitrile inhibitors of cathepsin K

The synthesis and biological profile of a novel series of potent and selective inhibitors of cysteine protease cathepsin K (Cat K) are described. Pharmacokinetic evaluation of 12 indicated that some members of this series could be suitable candidates to develop new orally active therapeutic agents for the treatment of osteoporosis.

3,4-Disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity

The synthesis of a series of highly potent and selective inhibitors of cathepsin K based on the 3,4-disubstituted azetidin-2-one warhead is reported. A high degree of potency and selectivity was achieved by introducing a basic nitrogen into the distal par

THIAZOLE DERIVATIVES AND USE THEREOF

The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

CYSTEINE PROTEASE INHIBITORS

A compound of the formula (II) wherein one of R1 and R2 is halo and the other is H or halo; R3 is C1-C4 straight or branched chain, optionally fluorinated, alkyl; R4 is H; or R3 together with R4 and the adjoining backbone carbon defines: a spiro-C5-C7 cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl, C1-C4 alkyl or C1-C4 haloalkyl; or optionally bridged with a methylene group; or a C4-C6 saturated heterocycle having a hetero atom selected from O, NRa, S, S(=O)2 ; where Ra is H, C1-C4 alkyl or CH3C(=O); R5 is independently selected from H or methyl; E is -C(=O)-, -S(=O)m-, -NR5S(=O)m-, -NR5C(=O)-, -OC(=O)-, R6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or hetorocycle; m is independently 0,1 or 2; are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.

Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K

We have prepared a series of achiral aminoacetonitriles, bearing tri-ring benzamide moieties and an aminocyclohexanecarboxylate residue at P2. This combination of binding elements resulted in sub-250 pM, reversible, selective, and orally bioavailable cathepsin K inhibitors. Lead compounds displayed single digit nanomolar inhibition in vitro (of rabbit osteoclast-mediated degradation of bovine bone). The best compound in this series, 39n (CRA-013783/L-006235), was orally bioavailable in rats, with a terminal half-life of over 3 h. 39n was dosed orally in ovariectomized rhesus monkeys once per day for 7 days. Collagen breakdown products were reduced by up to 76% dose-dependently. Plasma concentrations of 39n above the bone resorption IC50 after 24 h indicated a correlation between functional cellular and in vivo assays. Inhibition of collagen breakdown by cathepsin K inhibitors suggests this mechanism of action may be useful in osteoporosis and other indications involving bone resorption.

Substituted 1,3-thiazole compounds, their production and use

(1) A 1,3-thiazole compound of which the 5-position is substituted with a 4-pyridyl group having a substituent including no aromatic group or (2) a 1,3-thiazole compound of which the 5-position is substituted with a pyridyl group having at the position adjacent to a nitrogen atom of the pyridyl group a substituent including no aromatic group has an excellent p38 MAP kinase inhibitory activity.

N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety

We previously reported the identification of (2S)-((2- benzoylphenyl)amino)-3-{4-[2-(5-methyl-2-phenyloxazol-4- yl)ethoxy]phenyl}propanoic acid (2) (PPARγ pK(i) = 8.94, PPARγ pEC50 = 9.47) as a potent and selective PPARγ agonist. We now report the expanded structure-activity relationship around the phenyl alkyl ether moiety by pursuing both a classical medicinal chemistry approach and a solid-phase chemistry approach for analogue synthesis. The solution-phase strategy focused on evaluating the effects of oxazole and phenyl ring replacements of the 2-(5-methyl-2-phenyloxazol-4-yl)ethyl side chain of 2 with several replacements providing potent and selective PPARγ agonists with improved aqueous solubility. Specifically, replacement of the phenyl ring of the phenyloxazole moiety with a 4-pyridyl group to give 2(S)-((2- benzoylphenyl)amino)-3-{4-[2-(5-methyl-2-pyridin-4-yloxazol-4- yl)ethoxy]phenyl}propionic acid (16) (PPARγ pK(i) = 8.85, PPARγ pEC50 = 8.74) or a 4-methylpiperazine to give 2(S)-((2-benzoylphenyl)amino)-3-(4- {2-[5-methyl-2-(4-methylpiperazin-1-yl)thiazol-4-yl]ethoxy}phenyl)propionic acid (24) (PPARγ pK(i) = 8.66, PPARγ pEC50 = 8.89) provided two potent and selective PPARγ agonists with increased solubility in pH 7.4 phosphate buffer and simulated gastric fluid as compared to 2. The second strategy took advantage of the speed and ease of parallel solid-phase analogue synthesis to generate a more diverse set of phenyl alkyl ethers which led to the identification of a number of novel, high-affinity PPARγ ligands (PPARγ pK(i)'s 6.98-8.03). The combined structure-activity data derived from the two strategies provide valuable insight on the requirements for PPARγ binding, functional activity, selectivity, and aqueous solubility.